Templeman Thomas 4

4 · Centessa Pharmaceuticals plc · Filed Jun 4, 2021

Form 4

Period: 2021-06-02

Chief Technology Officer

Transactions

Purchase
Ordinary Shares
2021-06-02$20.00/sh+250$5,000→ 250 total
Award
Share Option (right to buy)
2021-04-20+500,338→ 500,338 total
Exercise: $9.42Exp: 2031-04-20→ Ordinary Shares (500,338 underlying)

Footnotes (5)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Share Split"). This amount has been adjusted to give effect to the Share Split.
[F3]This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3
[F4]25% of the shares subject to such option shall vest and become exercisable on May 17, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
[F5]Represented A Ordinary Shares that were redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.

Documents

1 file